Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMG-04
- Development stage
- Preclinical
- Lead developer
- RxOmeg Therapeutics
- Modality
- Small Molecules
01
Overview
RMG-04 is an investigational therapeutic candidate developed by RxOmeg Therapeutics (also known as Romeg Therapeutics) for the treatment of Sjögren's disease and other rheumatological conditions. Currently in the IND-enabling or preclinical stage, RMG-04 is being developed in conjunction with a companion diagnostic intended to identify patient subpopulations most likely to respond to the treatment. The specific mechanism of action and molecular target have not been publicly disclosed, but the program represents a precision medicine approach to treating autoimmune-driven sicca syndrome and related rheumatology indications.
Beyond the preview
Go deeper on RMG-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMG-04.